CA3240997A1 - Treatment of lung conditions with integrin subunit alpha 1 (itga1) inhibitors - Google Patents

Treatment of lung conditions with integrin subunit alpha 1 (itga1) inhibitors Download PDF

Info

Publication number
CA3240997A1
CA3240997A1 CA3240997A CA3240997A CA3240997A1 CA 3240997 A1 CA3240997 A1 CA 3240997A1 CA 3240997 A CA3240997 A CA 3240997A CA 3240997 A CA3240997 A CA 3240997A CA 3240997 A1 CA3240997 A1 CA 3240997A1
Authority
CA
Canada
Prior art keywords
itga1
nucleic acid
acid molecule
variant
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3240997A
Other languages
English (en)
French (fr)
Inventor
Manuel Allen Revez FERREIRA
Julie E. HOROWITZ
Katherine Siminovitch
Goncalo Abecasis
Aris BARAS
Maria Cristina Suciu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3240997A1 publication Critical patent/CA3240997A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3240997A 2021-12-17 2022-12-16 Treatment of lung conditions with integrin subunit alpha 1 (itga1) inhibitors Pending CA3240997A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291194P 2021-12-17 2021-12-17
US63/291,194 2021-12-17
PCT/US2022/081750 WO2023114969A2 (en) 2021-12-17 2022-12-16 Treatment of lung conditions with integrin subunit alpha 1 (itga1) inhibitors

Publications (1)

Publication Number Publication Date
CA3240997A1 true CA3240997A1 (en) 2023-06-22

Family

ID=85158395

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3240997A Pending CA3240997A1 (en) 2021-12-17 2022-12-16 Treatment of lung conditions with integrin subunit alpha 1 (itga1) inhibitors

Country Status (7)

Country Link
US (1) US20230192864A1 (https=)
EP (1) EP4448766A2 (https=)
JP (1) JP2024545873A (https=)
CN (1) CN118804976A (https=)
CA (1) CA3240997A1 (https=)
MX (1) MX2024007460A (https=)
WO (1) WO2023114969A2 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
JP2017510552A (ja) * 2014-02-07 2017-04-13 イーフェクター セラピューティクス， インコーポレイテッド 線維性疾患を治療するための方法
EP3458157A4 (en) * 2016-05-19 2020-05-27 Momenta Pharmaceuticals, Inc. METHOD FOR TREATING DISEASES RELATING TO FIBROSE AND SYSTEMIC Sclerosis
WO2018159432A1 (ja) * 2017-03-03 2018-09-07 ロート製薬株式会社 間葉系幹細胞及び医薬組成物
CN111643649A (zh) * 2020-05-20 2020-09-11 博奥生物集团有限公司 防治免疫相关疾病的中药材及其组合物

Also Published As

Publication number Publication date
CN118804976A (zh) 2024-10-18
WO2023114969A2 (en) 2023-06-22
JP2024545873A (ja) 2024-12-13
US20230192864A1 (en) 2023-06-22
EP4448766A2 (en) 2024-10-23
MX2024007460A (es) 2024-07-09
WO2023114969A3 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
CA3191030A1 (en) Treatment of sepsis with pcsk9 and ldlr modulators
CA3167756A1 (en) Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors
CA3181178A1 (en) Kelch domain containing 7b (klhdc7b) variants and uses thereof
CA3237033A1 (en) Methods of treating headaches and migraines with sodium voltage-gated channel alpha subunit 11 (scn11a) inhibitors
CA3219620A1 (en) Treatment of psoriasis with interferon induced helicase c domain 1 (ifih1) inhibitors
CA3224355A1 (en) Methods of treating a metabolic disorder with mitogen-activated protein kinase kinase kinase 15 (map3k15) inhibitors
US20230192864A1 (en) Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors
CA3218042A1 (en) Treatment of cerebrovascular disease with neurogenic locus notch homolog protein 3 (notch3) agents
EP4363585A1 (en) Methods of treating decreased bone mineral density with kringle containing transmembrane protein 1 (kremen1) inhibitors
US20250136996A1 (en) Treatment of smoking with cholinergic receptor nicotinic beta 3 subunit (chrnb3) inhibitors
CA3222964A1 (en) Methods of treating asthma with solute carrier family 27 member 3 (slc27a3) inhibitors
CA3223334A1 (en) Treatment of cognitive impairment with alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (st6galnac5) inhibitors
CA3222828A1 (en) Treatment of hypertension with solute carrier family 9 isoform a3 regulatory factor 2 (slc9a3r2) inhibitors
CA3232251A1 (en) Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors
CA3225778A1 (en) Methods of treating skin cancer with carboxypeptidase vitellogenic like (cpvl) inhibitors
CA3211435A1 (en) Treatment of liver disease with ring finger protein 213 (rnf213) inhibitors
WO2023064850A1 (en) Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
CN118613584A (zh) 使用内质网氨基肽酶1(erap1)抑制剂治疗葡萄膜炎

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251121